MedPath

How Common is Hypoglycaemia in Older People With Diabetes Who Fall?

Not Applicable
Completed
Conditions
Diabetes
Hypoglycaemia
Interventions
Device: Continuous glucose monitoring (Dexcom G6)
Registration Number
NCT05470842
Lead Sponsor
University of East Anglia
Brief Summary

The purpose of this study is to use 24 hour continuous glucose monitoring in older patients with diabetes who present with symptoms of falls, or dizziness, or confusion, that may indicate hypoglycaemia.

Detailed Description

Background and study aims Patients with diabetes can be treated with medications (such as insulin or sulfonylureas) that can lower the sugar levels too much (hypos). A hypo means that the brain does not get enough energy. A person can become confused, dizzy, pass out, and/or have a fall.

Older people with diabetes often seek treatment in hospital for symptoms such as falls, dizziness or feeling muddled. Health care professionals will order tests to investigate the possible causes for the fall, being muddled or dizzy, which can include a review of medications, checking blood pressures and the heart.

However, it has previously been difficult to obtain 24-hour blood sugar monitoring in older people with diabetes to check if hypos could be an important contributing factor to their falls and dizzy spells.

Continuous Glucose Monitoring (CGM) allows non-stop monitoring with a sensor that sits just under the skin. This sends sugar readings to a smartphone every few minutes (via Bluetooth) for 10 days. This enables full evaluation of the amount of time a person's sugar is in the target range, and the time in the low/high ranges. Medical research with CGM has revealed that some older people are suffering from substantial periods of hypos that they are not aware of.

During this study, older people with diabetes will be asked to wear a CGM device for 10 days to investigate possibility of hypos.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
12
Inclusion Criteria
  • 75 years and older with diabetes
  • Treated with glucose-medications which carry a high risk of hypoglycaemia (sulfonylureas and/or insulin)
  • Presenting to hospital with a fall and/or symptoms suggestive of unrecognised hypoglycaemia (such as dizziness, feeling muddled).
Exclusion Criteria
  • Treatment with metformin alone
  • Lack of capacity,
  • Not willing to participate,
  • Terminal illness (less than one-year life expectancy).
  • Evidence of bruising, bleeding, cellulitis and/or skin tears on the upper arms or abdomen.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Continuous glucose monitoringContinuous glucose monitoring (Dexcom G6)Continuous Glucose Monitoring Device for up to 10 days
Primary Outcome Measures
NameTimeMethod
Proportion of Participants With Captured Hypoglycaemia10 days

Number of patients who experienced more than 15 minutes of hypoglycaemia within the 10-day sensor lifespan and data capture period.

Secondary Outcome Measures
NameTimeMethod
Overall Time in Range (Average)10 days

The percentage of time glucose concentrations in the 10-day monitoring period that were within the defined target range (3.9 - 10.0 mmol) as specified by international consensus.

Emergency Department Re-attendances and/or Hospital Re-admissions for Falls, Fractures, Heart Attacks, Ischaemic Strokes and Death Within 30 Days30 days

Number of participants with hospital admissions and emergency department attendances within 30 days of sensor monitoring. Review of hospital records to ascertain date of admission and clinical presentation.

Trial Locations

Locations (1)

University of East Anglia

🇬🇧

Norwich, Norfolk, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath